WO2007013896A3 - Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors - Google Patents
Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors Download PDFInfo
- Publication number
- WO2007013896A3 WO2007013896A3 PCT/US2006/018726 US2006018726W WO2007013896A3 WO 2007013896 A3 WO2007013896 A3 WO 2007013896A3 US 2006018726 W US2006018726 W US 2006018726W WO 2007013896 A3 WO2007013896 A3 WO 2007013896A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrrol
- protein kinase
- kinase inhibitors
- pyridine derivatives
- derivatives protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0610066-0A BRPI0610066A2 (en) | 2005-05-17 | 2006-05-16 | compounds that modulate c-kit and c-fms activity and uses for these |
MX2007014377A MX2007014377A (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors. |
NZ563444A NZ563444A (en) | 2005-05-17 | 2006-05-16 | Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors |
AU2006272951A AU2006272951A1 (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
CA002608733A CA2608733A1 (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
EP06813186A EP1885723A2 (en) | 2005-05-17 | 2006-05-16 | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
JP2008512402A JP2008545652A (en) | 2005-05-17 | 2006-05-16 | Compounds that modulate c-kit and c-fms activity and uses thereof |
IL187344A IL187344A0 (en) | 2005-05-17 | 2007-11-13 | Compounds modulating c-kit and c-fms activity and uses therefor |
NO20075992A NO20075992L (en) | 2005-05-17 | 2007-11-23 | Compounds that modulate C-Kit and C-FMS activity and uses thereof |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68206305P | 2005-05-17 | 2005-05-17 | |
US68205105P | 2005-05-17 | 2005-05-17 | |
US68204205P | 2005-05-17 | 2005-05-17 | |
US60/682,063 | 2005-05-17 | ||
US60/682,051 | 2005-05-17 | ||
US60/682,042 | 2005-05-17 | ||
US69275005P | 2005-06-22 | 2005-06-22 | |
US69296005P | 2005-06-22 | 2005-06-22 | |
US60/692,960 | 2005-06-22 | ||
US60/692,750 | 2005-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007013896A2 WO2007013896A2 (en) | 2007-02-01 |
WO2007013896A3 true WO2007013896A3 (en) | 2007-05-31 |
Family
ID=37683773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/018726 WO2007013896A2 (en) | 2005-05-17 | 2006-05-16 | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
Country Status (14)
Country | Link |
---|---|
US (2) | US7846941B2 (en) |
EP (1) | EP1885723A2 (en) |
JP (1) | JP2008545652A (en) |
KR (1) | KR20080027775A (en) |
AU (1) | AU2006272951A1 (en) |
BR (1) | BRPI0610066A2 (en) |
CA (1) | CA2608733A1 (en) |
CR (1) | CR9591A (en) |
EC (1) | ECSP077985A (en) |
IL (1) | IL187344A0 (en) |
MX (1) | MX2007014377A (en) |
NO (1) | NO20075992L (en) |
NZ (1) | NZ563444A (en) |
WO (1) | WO2007013896A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
US8865735B2 (en) | 2011-02-21 | 2014-10-21 | Hoffman-La Roche Inc. | Solid forms of a pharmaceutically active substance |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9169250B2 (en) | 2006-11-22 | 2015-10-27 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1696920T3 (en) | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Compounds and methods for development of ret modulators |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
DK1893612T3 (en) * | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Pyrrole [2,3-B] pyridine derivatives as protein kinase inhibitors |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
EP1938842A4 (en) * | 2005-09-01 | 2013-01-09 | Eisai R&D Man Co Ltd | Method for preparation of pharmaceutical composition having improved disintegradability |
US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
RU2448708C3 (en) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER |
EP2027087A2 (en) * | 2006-05-18 | 2009-02-25 | MannKind Corporation | Intracellular kinase inhibitors |
PE20081581A1 (en) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
EP2094701A2 (en) | 2006-12-21 | 2009-09-02 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
AU2008331733A1 (en) | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta |
AR070535A1 (en) * | 2008-02-29 | 2010-04-14 | Array Biopharma Inc | RAF INHIBITING COMPOUNDS AND METHODS FOR USE |
WO2009111280A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
EP2265609B1 (en) * | 2008-02-29 | 2012-09-05 | Array Biopharma, Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
AR072657A1 (en) | 2008-02-29 | 2010-09-15 | Genentech Inc | RAF INHIBITING COMPOUNDS AND METHODS FOR USE |
PE20091846A1 (en) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8110576B2 (en) * | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
EP2313411A1 (en) * | 2008-06-10 | 2011-04-27 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
US8592448B2 (en) * | 2008-11-20 | 2013-11-26 | OSI Pharmaceuticals, LLC | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines |
MX2011005597A (en) * | 2008-12-05 | 2011-06-16 | Hoffmann La Roche | Pyrrolopyrazinyl urea kinase inhibitors. |
WO2010111527A1 (en) * | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
BR112012003462A2 (en) | 2009-08-24 | 2016-02-23 | Ascepion Pharmaceuticals Inc | "compound, pharmaceutical composition, and method for treating a patient having a protein kinase mediated condition." |
CA2772316A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase |
PE20121335A1 (en) | 2009-11-18 | 2012-10-12 | Plexxikon Inc | AMIDA-DERIVED COMPOUNDS AS RAF KINASES INHIBITORS |
CN102822170B (en) * | 2009-12-21 | 2014-12-10 | 阵列生物制药公司 | Substituted N-(1H-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cFMS inhibitors |
WO2011079133A2 (en) | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
AU2010339444A1 (en) | 2009-12-30 | 2012-07-19 | Arqule, Inc. | Substituted pyrrolo-aminopyrimidine compounds |
TWI510487B (en) * | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
EP2569315A1 (en) | 2010-05-14 | 2013-03-20 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
AR081039A1 (en) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | QUINASA FUSIONED BICYCLE INHIBITORS |
JP5941069B2 (en) | 2011-02-07 | 2016-06-29 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for kinase regulation and indications therefor |
MX2013011612A (en) * | 2011-04-05 | 2013-10-17 | Pfizer Ltd | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases. |
KR101762999B1 (en) | 2011-04-18 | 2017-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Therapeutic agent for tumor |
WO2012158658A1 (en) | 2011-05-16 | 2012-11-22 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
RU2631487C2 (en) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Kinases modulation and indications for its use |
ES2705950T3 (en) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds |
PL2797888T3 (en) | 2011-12-31 | 2016-12-30 | Fused tricyclic compounds as raf kinase inhibitors | |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2885259A1 (en) | 2012-10-04 | 2014-04-10 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
CN105308036B (en) | 2012-12-21 | 2019-06-21 | 普莱希科公司 | The Compounds and methods for and its indication adjusted for kinases |
CN104755463A (en) | 2012-12-21 | 2015-07-01 | 卫材R&D管理有限公司 | Amorphous form of quinoline derivative, and method for producing same |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
HUE039380T2 (en) | 2013-03-15 | 2018-12-28 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
KR102204279B1 (en) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
MX2015015966A (en) | 2013-05-30 | 2016-04-13 | Plexxikon Inc | Compounds for kinase modulation, and indications therefor. |
WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
MX2017001980A (en) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same. |
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
LT3263106T (en) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP3757104A1 (en) | 2015-05-06 | 2020-12-30 | Plexxikon Inc. | Solid forms of a compound modulating kinases |
HUE047657T2 (en) | 2015-05-06 | 2020-05-28 | Plexxikon Inc | Synthesis of 1h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases |
CN107801379B (en) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | Anticancer agent |
MX2018000880A (en) * | 2015-07-20 | 2018-08-24 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors. |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
KR20180052757A (en) | 2015-09-21 | 2018-05-18 | 플렉시콘 인코퍼레이티드 | Heterocyclic compounds and uses thereof |
RU2018123825A (en) | 2015-12-07 | 2020-01-15 | Плексксикон Инк. | COMPOUNDS AND METHODS FOR MODULATION OF KINASES, AND INDICATIONS FOR THIS |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
AU2017232610B2 (en) | 2016-03-16 | 2021-07-22 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
SG11201901197PA (en) | 2016-08-24 | 2019-03-28 | Arqule Inc | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
RU2770404C2 (en) * | 2016-09-16 | 2022-04-15 | Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) | Traf 6 inhibitors |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
WO2018136202A2 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
CN110461841B (en) * | 2017-06-19 | 2020-09-15 | 上海和誉生物医药科技有限公司 | Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof |
CN110944670B (en) | 2017-07-25 | 2023-03-10 | 普莱希科公司 | Formulations of compounds for modulating kinases |
EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
JP7175309B2 (en) | 2017-10-27 | 2022-11-18 | プレキシコン インコーポレーテッド | Formulations of compounds that modulate kinases |
BR112020015072A2 (en) | 2018-01-31 | 2021-01-05 | Heparegenix Gmbh | PROTEIN KINASE MKK4 INHIBITORS TO PROMOTE LIVER REGENERATION, OR REDUCE, OR PREVENT HEPATOCYT DEATH |
CN112119072A (en) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | Compounds and methods for IDO and TDO modulation, and indications thereof |
EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
SG11202012732UA (en) | 2018-07-16 | 2021-02-25 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
JP2022504905A (en) | 2018-10-16 | 2022-01-13 | ノバルティス アーゲー | Tumor mutation loading alone or in combination with immune markers as a biomarker to predict response to targeted therapy |
US11446287B2 (en) | 2019-04-09 | 2022-09-20 | Opna Immuno-Oncology Sa | Compounds and methods for EP300 or CBP modulation and indications therefor |
WO2021144360A1 (en) | 2020-01-17 | 2021-07-22 | F. Hoffmann-La Roche Ag | Small molecule csf-1r inhibitors in therapeutic and cosmetic uses |
TW202206422A (en) | 2020-04-23 | 2022-02-16 | 美商普雷辛肯公司 | Compounds and methods for cd73 modulation and indications therefor |
CN116322690A (en) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | Combination pharmaceutical anticancer therapies |
EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
JP2024511373A (en) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | Biomarkers and their use for cancer |
CN115557985B (en) * | 2022-12-06 | 2023-03-10 | 成都泰蓉生物科技有限公司 | Method for selectively cracking C-S bond in thioether to form silane |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014808A1 (en) * | 1992-12-23 | 1994-07-07 | Farmitalia Carlo Erba Srl | Vinylene-azaindole derivatives and process for their preparation |
WO2004016610A1 (en) * | 2002-08-14 | 2004-02-26 | Astrazeneca Ab | Substituted pyrrolopyridines |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US617687A (en) * | 1899-01-10 | Vapor-burning apparatus | ||
US2234705A (en) * | 1940-04-12 | 1941-03-11 | Eastman Kodak Co | Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids |
US2413258A (en) * | 1942-07-07 | 1946-12-24 | United Gas Improvement Co | Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters |
DE2413258A1 (en) | 1974-03-20 | 1975-10-02 | Bayer Ag | Herbicidal N-(alkoxycarbonyl-phenyl)-N'-methyl-urea derivs - prepd by reacting alkoxycarbonyl-phenyl isocyanates with methylamines |
GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
US4664504A (en) * | 1983-01-20 | 1987-05-12 | Tokyo Shibaura Denki Kabushiki Kaisha | Image forming apparatus |
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
DE3483099D1 (en) | 1984-03-15 | 1990-10-04 | Immunex Corp | TEST FOR IMMEDIATELY DETECTING LIGANDS, TEST SET AND ITS PRODUCTION. |
US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5658775A (en) | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
JP3082204B2 (en) | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | Recombinant retrovirus with an amphotropic and ecotropic host range |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
DE4022414A1 (en) * | 1990-07-13 | 1992-01-16 | Bayer Ag | SUBSTITUTED PYRROLO-PYRIDINE |
EP0659209A1 (en) | 1991-07-26 | 1995-06-28 | The University Of Rochester | Cancer therapy utilizing malignant cells |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
FR2687402B1 (en) * | 1992-02-14 | 1995-06-30 | Lipha | NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM. |
JPH05236997A (en) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | Chip for catching polynucleotide |
ATE184008T1 (en) * | 1993-03-01 | 1999-09-15 | Merck Sharp & Dohme | PYRROLOPYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS |
US5576319A (en) * | 1993-03-01 | 1996-11-19 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
NZ261593A (en) * | 1993-03-01 | 1996-09-25 | Merck Sharp & Dohme | 3-piperazinylmethly-1h-indolopyridine derivatives and pharmaceutical compositions |
ATE366741T1 (en) * | 1993-05-27 | 2007-08-15 | Aventis Pharma Inc | TOPOLOGICALLY SEPARATE, SOLID-PHASE CODING LIBRARIES |
US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US5965452A (en) * | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
GB9416162D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5837815A (en) | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
GB9503400D0 (en) | 1995-02-21 | 1995-04-12 | Merck Sharp & Dohme | Therpeutic agents |
GB2298199A (en) * | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US6117681A (en) * | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
GB2299581A (en) | 1995-04-07 | 1996-10-09 | Merck Sharp & Dohme | 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes |
GB9507291D0 (en) * | 1995-04-07 | 1995-05-31 | Merck Sharp & Dohme | Therapeutic agents |
US6110456A (en) * | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5856174A (en) * | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5866411A (en) * | 1995-09-08 | 1999-02-02 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
WO1997016533A1 (en) | 1995-10-31 | 1997-05-09 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
WO1997046313A1 (en) | 1996-06-07 | 1997-12-11 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
WO1998039471A1 (en) * | 1997-03-07 | 1998-09-11 | Tropix, Inc. | Protease inhibtor assay |
US6096718A (en) * | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
US6235769B1 (en) * | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6826296B2 (en) * | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
US6161776A (en) * | 1997-08-12 | 2000-12-19 | Nibco Inc. | Multi-layered, porous mat turf irrigation apparatus and method |
WO1999009217A1 (en) | 1997-08-15 | 1999-02-25 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
WO1999013313A1 (en) | 1997-09-11 | 1999-03-18 | Genovations, Inc. | Method of making high density arrays |
US6178384B1 (en) * | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
US6465178B2 (en) * | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
WO1999063929A2 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US6113913A (en) * | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
US6277489B1 (en) * | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US6221653B1 (en) * | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
FR2793793B1 (en) * | 1999-05-19 | 2004-02-27 | Adir | NOVEL SUBSTITUTED DIMERIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
US6653151B2 (en) * | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
DE60029138T2 (en) * | 1999-12-22 | 2007-06-06 | Sugen, Inc., San Francisco | Use of indolinone compounds for the production of pharmaceuticals for the modulation of the function c-kit protein tyrosine kinase |
JP4204326B2 (en) | 2001-04-11 | 2009-01-07 | 千寿製薬株式会社 | Visual function disorder improving agent |
WO2002085896A1 (en) | 2001-04-24 | 2002-10-31 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan |
GB0114417D0 (en) * | 2001-06-13 | 2001-08-08 | Boc Group Plc | Lubricating systems for regenerative vacuum pumps |
EP1267111A1 (en) | 2001-06-15 | 2002-12-18 | Dsm N.V. | Pressurized fluid conduit |
WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
UA75425C2 (en) | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
US6858860B2 (en) * | 2001-07-24 | 2005-02-22 | Seiko Epson Corporation | Apparatus and method for measuring natural period of liquid |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
WO2003037862A1 (en) | 2001-10-30 | 2003-05-08 | Nippon Shinyaku Co., Ltd. | Amide derivatives and drugs |
US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
US6884889B2 (en) | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
IL164082A0 (en) | 2002-03-28 | 2005-12-18 | Eisai Co Ltd | Azaindole derivatives and pharmaceutical compositions containing the same |
WO2003082868A1 (en) | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6878887B2 (en) * | 2002-08-07 | 2005-04-12 | Matsushita Electric Industrial Co., Ltd. | Anti-malfunction mechanism for variable output device |
EP2277551B1 (en) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
CA2503905A1 (en) * | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US7696225B2 (en) * | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
SE0300119D0 (en) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300120D0 (en) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
AU2004213375A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-Hydroxytryptamine-6 ligands |
US20050170431A1 (en) * | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
US20050164300A1 (en) * | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
DE10357510A1 (en) | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroaryl-substituted benzenes |
PL1696920T3 (en) * | 2003-12-19 | 2015-03-31 | Plexxikon Inc | Compounds and methods for development of ret modulators |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0330043D0 (en) * | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
GB0403635D0 (en) | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
DK1730146T3 (en) | 2004-03-30 | 2011-08-15 | Vertex Pharma | Azaindoles useful as inhibitors of JAK and other protein kinases |
WO2005116035A1 (en) * | 2004-05-27 | 2005-12-08 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
WO2006009797A1 (en) * | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
EP2325184A1 (en) | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7452993B2 (en) * | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7709645B2 (en) * | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
ATE524467T1 (en) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | NOVEL AZA HETEROCYCLES AS KINASE INHIBITORS |
AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
DK1893612T3 (en) | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Pyrrole [2,3-B] pyridine derivatives as protein kinase inhibitors |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
PE20081581A1 (en) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
TW200908968A (en) * | 2007-05-29 | 2009-03-01 | Sgx Pharmaceuticals Inc | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
-
2006
- 2006-05-16 AU AU2006272951A patent/AU2006272951A1/en not_active Abandoned
- 2006-05-16 US US11/435,381 patent/US7846941B2/en active Active
- 2006-05-16 KR KR1020077029428A patent/KR20080027775A/en not_active Application Discontinuation
- 2006-05-16 EP EP06813186A patent/EP1885723A2/en not_active Withdrawn
- 2006-05-16 MX MX2007014377A patent/MX2007014377A/en active IP Right Grant
- 2006-05-16 NZ NZ563444A patent/NZ563444A/en not_active IP Right Cessation
- 2006-05-16 JP JP2008512402A patent/JP2008545652A/en active Pending
- 2006-05-16 CA CA002608733A patent/CA2608733A1/en not_active Abandoned
- 2006-05-16 BR BRPI0610066-0A patent/BRPI0610066A2/en not_active IP Right Cessation
- 2006-05-16 WO PCT/US2006/018726 patent/WO2007013896A2/en active Application Filing
-
2007
- 2007-11-13 IL IL187344A patent/IL187344A0/en unknown
- 2007-11-23 NO NO20075992A patent/NO20075992L/en not_active Application Discontinuation
- 2007-12-07 EC EC2007007985A patent/ECSP077985A/en unknown
- 2007-12-14 CR CR9591A patent/CR9591A/en not_active Application Discontinuation
-
2010
- 2010-12-01 US US12/958,376 patent/US20110166174A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014808A1 (en) * | 1992-12-23 | 1994-07-07 | Farmitalia Carlo Erba Srl | Vinylene-azaindole derivatives and process for their preparation |
WO2004016610A1 (en) * | 2002-08-14 | 2004-02-26 | Astrazeneca Ab | Substituted pyrrolopyridines |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9169250B2 (en) | 2006-11-22 | 2015-10-27 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9487515B2 (en) | 2006-11-22 | 2016-11-08 | Plexxikon Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US9469640B2 (en) | 2007-07-17 | 2016-10-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
US8741920B2 (en) | 2009-08-03 | 2014-06-03 | Hoffmann-La Roche, Inc. | Process for the manufacture of pharmaceutically active compounds |
US9096593B2 (en) | 2009-11-06 | 2015-08-04 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8865735B2 (en) | 2011-02-21 | 2014-10-21 | Hoffman-La Roche Inc. | Solid forms of a pharmaceutically active substance |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
Also Published As
Publication number | Publication date |
---|---|
MX2007014377A (en) | 2008-02-06 |
KR20080027775A (en) | 2008-03-28 |
CA2608733A1 (en) | 2007-02-01 |
US20070032519A1 (en) | 2007-02-08 |
ECSP077985A (en) | 2008-01-23 |
CR9591A (en) | 2008-03-26 |
AU2006272951A1 (en) | 2007-02-01 |
JP2008545652A (en) | 2008-12-18 |
US7846941B2 (en) | 2010-12-07 |
NO20075992L (en) | 2008-02-13 |
EP1885723A2 (en) | 2008-02-13 |
IL187344A0 (en) | 2008-04-13 |
BRPI0610066A2 (en) | 2010-05-25 |
WO2007013896A2 (en) | 2007-02-01 |
US20110166174A1 (en) | 2011-07-07 |
NZ563444A (en) | 2011-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007013896A3 (en) | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors | |
WO2008063888A3 (en) | Compounds modulating c-fms and/or c-kit activity and uses therefor | |
TW200616632A (en) | Compounds modulating c-kit activity and uses therefor | |
WO2006078287A3 (en) | Pde4b inhibitors and uses therefor | |
WO2007079164A3 (en) | Protein kinase inhibitors | |
WO2008121687A3 (en) | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | |
WO2006124863A3 (en) | Pyrrolopyridine derivatives as protein kinase inhibitors | |
WO2007016674A3 (en) | 2-aminoaryl pyridines as protein kinases inhibitors | |
WO2007111904A3 (en) | C-met protein kinase inhibitors for the treatment of proliferative disorders | |
WO2005108358A3 (en) | Pyrrolidine derivatives useful as bace inhibitors | |
NO20076659L (en) | Pyrrolo (2,3-B) pyridine derivatives as protein kinase inhibitors | |
WO2004089286A3 (en) | Novel compounds and compositions as protein kinase inhibitors | |
WO2006050109A3 (en) | Novel kinase inhibitors | |
NO20063861L (en) | 2- (3-substituted aryl) amine-4-arylthiazoles as tyrosine kinase inhibitors | |
UY28970A1 (en) | MODULATING COMPOUNDS OF C-KIT ACTIVITY AND USES OF THE SAME | |
WO2006004884A3 (en) | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | |
WO2005116025A3 (en) | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
WO2007056221A3 (en) | Aminopyrimidines useful as kinase inhibitors | |
WO2007095223A3 (en) | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases | |
UA98449C2 (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
ATE548363T1 (en) | 3,5-DISUBSTITUTED PYRID-2-ONES, WHICH ARE SUITABLE AS INHIBITORS OF THE TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | |
WO2009006389A8 (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
NO20072795L (en) | Pyrazole [1,5-a] pyrimidines useful as inhibitors of protein kinases | |
WO2007067781A3 (en) | 9-membered heterobicyclic compounds as inhibitors of protein kinases | |
WO2006034093A3 (en) | 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680026005.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 187344 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4363/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502546 Country of ref document: PH Ref document number: 563444 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2608733 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/014377 Country of ref document: MX Ref document number: 07121351 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2008512402 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006272951 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006813186 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2007-009591 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007142326 Country of ref document: RU Ref document number: 1020077029428 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006272951 Country of ref document: AU Date of ref document: 20060516 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0610066 Country of ref document: BR Kind code of ref document: A2 |